Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye

Cornea

Volumn 31, Issue 11, 2012, Pages 1299-1303

  De Paiva, Cintia S ^a   Schwartz, C Eric ^b   Gjörstrup, Per ^b   Pflugfelder, Stephen C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Resolvyx Pharmaceuticals Inc   (United States)

Author keywords

antiinflammatory; conjunctival goblet cell; corneal epithelium; dry eye; mouse; resolvin E1

Indexed keywords

IMMUNOMODULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PRODRUG; RESOLVIN E1; RX 10001; RX 10005; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL DENSITY; CELL LOSS; CONJUNCTIVA; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA PERFORATION; CORNEA PERMEABILITY; CORNEAL EPITHELIAL BARRIER DISRUPTION; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRY EYE; ENZYME ACTIVATION; EYE PROTECTION; FEMALE; GOBLET CELL; HUMIDITY; IMMUNOREGULATION; MALE; MOUSE; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL;

ADMINISTRATION, TOPICAL; ANIMALS; BIOLOGICAL TRANSPORT; CELL COUNT; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; EICOSAPENTAENOIC ACID; EPITHELIUM, CORNEAL; FEMALE; FLUORESCENT DYES; GOBLET CELLS; MALE; MICE; MICE, INBRED C57BL; PRODRUGS;

EID: 84867404595     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31823f789e     Document Type: Article

References (44)

1. Bjerrum KB. Keratoconjunctivitis sicca and primary Sjögren's syndrome in a Danish population aged 30-60 years. Acta Ophthalmol Scand. 1997; 75:281-286.
2. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114-1119.
3. Schaumberg DA, Sullivan DA, Buring JA, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326.
4. Lemp MA. Management of dry eye disease. Am J Manag Care. 2008;14: S88-S101.
5. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf. 2004;2: 124-130.
6. Tomlinson A, Khanal S, Ramaesh K, et al. Tear film osmolarity: Determination of a referent for dry eye diagnosis. Invest Ophthamol Vis Sci. 2006;47:4309-4315.
7. Bron AJ, Yokoi N, Gaffney E, et al. Predicted phenotypes of dry eye: Proposed consequences of its natural history. Ocul Surf. 2009;7:78-92.
8. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45: 4293-4301.
9. Luo L, Li DQ, Corrales RM, et al. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 2005;31:186-193.
10. Li DQ, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL-1b, TNF-a and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. 2006;82:588-596.
11. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1in tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283-2292.
12. Yoon KC, Jeong IY, Park YG, et al. Interleukin-6 and tumor necrosis factor-a levels in tears of patients with dry eye syndrome. Cornea. 2007; 26:431-437.
13. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjögren's Syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006;176:3950-3957.
14. Pflugfelder SC, Stern ME, et al. Immunoregulation on the ocular surface: 2nd Cullen Symposium. Ocul Surf. 2009;7:67-77.
15. Luo L, Li DQ, Pflugfelder SC. Hyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathways. Cornea. 2007;26:452-460.
16. Yeh S, Song XJ, Farley W, et al. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci. 2003;44: 124-129.
17. Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res. 2004;78:379-388.
18. Gipson IK. The ocular surface: The challenge to enable and protect vision: The Friedenwald lecture. Invest Ophthalmol Vis Sci. 2007;48: 4391-4398.
19. Pflugfelder SC, Tseng SC, Yoshino K, et al. Correlation of goblet cell densities and mucosal epithelial membrane mucin (MEM) expression with rose bengal staining in patients with ocular irritation. Ophthalmology. 1997;104:223-225.
20. Serhan CN, Chiang N, van Dyke TE. Resolving inflammation: Dual antiinflammation and pro-resolution lipid mediators. Nature Rev Immunol. 2008;8:347-361.
21. Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipidderived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197-1204.
22. Arita M, Yoshida M, Hong S, et al. Resolvin E1 an endogenous lipid mediator derived from omegas-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A. 2005;102:7671-7676.
23. Gjörstrup P, Dubrovskiy A, Dodge D, et al. Resolvin E1 (RvE1) an endogenously formed immune modulator attenuates clinical signs of autoimmune disease in the Rat CIA model concurrent with inhibition of T-cell dependent cytokines in mixed cell populations from draining lymph nodes. Presented at: The Association for Research in Vision and Ophthalmology; May 3-7, 2009; Fort Lauderdale, FL. A819.
24. Haworth O, Cernadas M, Yang R, et al. Resolvin E1 regulates interleukin 23, interferon g and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol. 2008;6:1-7.
25. Zhang F, Chen N, Pan Z, et al. EGF receptor transactivation mediates resolvin-induced increases in corneal epithelial cell migration. Invest Ophthalmol Vis Sci. 2010;51:5601-5609.
26. Pan Z, Gjorstrup P, Reinach P. Resolvins inhibit hypertonicity-induced proinflammatory cytokine release by suppressing MAPK pathway activation in human corneal epithelial cells. Presented at: The Association for Research in Vision and Ophthalmology; April 27 to May 1, 2008; Fort Lauderdale. A125.
27. Dursun D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002;43:632-638.
28. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye. J Pharm Sci. 1998; 87:1479-1488.
29. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131-1135.
30. Sjöquist B, Basu S, Byding P, et al. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metabol Dispos. 1998;26:745-754.
31. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(suppl 1):S6-S12.
32. Pflugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea. 1998;17: 38-56.
33. Bron AJ, Evans VE, Smith AJ. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22:640-650.
34. Horwart-Winter J, Berghold A, Schmut O, et al. Evaluation of the clinical course of dry eye syndrome. Arch Ophthalmol. 2003;121:1364-1368.
35. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated cyclosporine. Arch Ophthalmol. 1999;120:330-337.
36. Murube J, Rivas L. Impression cytology on conjunctiva and cornea in dry eye patients establishes a correlation between squamous metaplasia and dry eye clinical severity. Eur J Ophthalmol. 2003;13:115-127.
37. Creagh EM, Conroy H, Martin SJ. Caspase-activation pathways in apoptosis and immunity. Immunol Rev. 2003;193:10-21.
38. Reinoso MA, Mukherjee PK, Gjörstrup P, et al. Oxidative stress-induced apoptosis and pro-inflammatory COX-2 expression are down-regulated by resolvins in retinal pigment epithelial (arpe-19) cells. Presented at: The Association for Research in Vision and Ophthalmology; April 27 to May 1, 2008; Fort Lauderdale. A2438.
39. Keyes KT, Ye Y, Lin Y, et al. Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2010;299: H153-H164.
40. Li N, HE J, Schwartz CE, et al. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther. 2010;26:431-439.
41. de Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006;47: 2847-2856.
42. de Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83:526-535.
43. Strong B, Farley W, Sten ME, et al. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005;24:80-85.
44. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337-342.